Affectis Pharmaceuticals AG
Industry
- Pharmaceuticals
Latest on Affectis Pharmaceuticals AG
The Heidelberg, Germany, based venture capital firm EMBL Ventures announced Dec. 7 it had raised €40 million ($55 million) in a first closing for its second fund, EMBL Technology II (ETF II). It is th
Mergers & Acquisitions /In Vitro Diagnostics Clovis Oncology Inc. Roche Roche Diagnostics Roche Molecular Systems Inc. On the same day it received rights to a solid tumor compound from Pfizer Inc.
Merck Serono (Merck KGaA) has signed an exclusive licensing agreement with Affectis Pharmaceuticals of Germany for the development and commercialisation of oral compounds targeting P2X7 receptors. The
In Vitro Diagnostics Aureon Laboratories Inc. Aureon Laboratories raises $7mm so far through late-stage round Feb. — Aureon Laboratories (molecular diagnostics for prostate cancer) has raised $7mm o